Gilead (GILD) stock gains as the company's new single-tablet HIV regimen is proven as effective as multi-tablet therapies in ...

A new Gilead study shows that a single-tablet combo of HIV-fighting drugs could help patients who today take multiple drugs.

Sagimet Bioscience’s denifanstat, a one-daily pill for the treatment of acne, has succeeded in a Phase III trial, with the biotech’s license partner Ascletis Bioscience set to submit the drug for ...